Contradictions in Focus: Analyzing U.S. Onshoring, Vial Market Growth, and Engineering Performance

Revenue and Segment Growth:
- Stevanato Group reported revenue growth of 8% in Q2 2025, with the BDS segment growing 10% and contributing significantly to this increase.
- The growth was driven by strong performance in the Biopharmaceutical and Diagnostic Solutions segment and a higher mix of high-value solutions.

High-Value Solutions Expansion:
- High-value solutions revenue increased by 13%, representing 42% of total revenue in Q2 2025.
- The growth in high-value syringes and EZ-fill cartridges and vials was primarily due to favorable secular trends, especially the rise in biologics, which are fueling strong demand for Stevanato's products.

Engineering Segment Challenges and Recovery:
- The Engineering segment saw a 2% revenue decline in Q2 2025, primarily due to lower revenue from legacy projects and timing of new order intake.
- Challenges were attributed to the execution of legacy projects and delays in new order timing, but operational progress is being made with an increase in customer site acceptance tests.

Capital Investment and Strategic Expansion:
- Stevanato Group is investing in new facilities in Fishers and Latina to increase capacity for high-value syringes and cartridge production.
- These investments are driven by the need to meet rising market demand for biologics and a strategic focus on high-value product offerings.